메뉴 건너뛰기




Volumn 6, Issue 1, 2011, Pages

Differences in reversion of resistance mutations to wild- type under structured treatment interruption and related increase in replication capacity

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE;

EID: 79551647687     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014638     Document Type: Article
Times cited : (14)

References (21)
  • 1
    • 0035864943 scopus 로고    scopus 로고
    • Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
    • Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, et al. (2001) Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344: 472-480.
    • (2001) N Engl J Med , vol.344 , pp. 472-480
    • Deeks, S.G.1    Wrin, T.2    Liegler, T.3    Hoh, R.4    Hayden, M.5
  • 2
    • 0037436291 scopus 로고    scopus 로고
    • Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response
    • Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, et al. (2003) Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. Aids 17: 361-370.
    • (2003) Aids , vol.17 , pp. 361-370
    • Deeks, S.G.1    Grant, R.M.2    Wrin, T.3    Paxinos, E.E.4    Liegler, T.5
  • 3
    • 33750317852 scopus 로고    scopus 로고
    • A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086
    • Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, et al. (2006) A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis 194: 1309-1318.
    • (2006) J Infect Dis , vol.194 , pp. 1309-1318
    • Benson, C.A.1    Vaida, F.2    Havlir, D.V.3    Downey, G.F.4    Lederman, M.M.5
  • 4
    • 72849148114 scopus 로고    scopus 로고
    • Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America
    • Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, et al. (2009) Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 49: 1582-1590.
    • (2009) Clin Infect Dis , vol.49 , pp. 1582-1590
    • Deeks, S.G.1    Gange, S.J.2    Kitahata, M.M.3    Saag, M.S.4    Justice, A.C.5
  • 6
    • 77954692660 scopus 로고    scopus 로고
    • Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
    • Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-333.
    • (2010) JAMA , vol.304 , pp. 321-333
    • Thompson, M.A.1    Aberg, J.A.2    Cahn, P.3    Montaner, J.S.4    Rizzardini, G.5
  • 7
    • 34247478025 scopus 로고    scopus 로고
    • The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient
    • Blick G, Kagan RM, Coakley E, Petropoulos C, Maroldo L, et al. (2007) The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient. J Infect Dis 195: 1250-1259.
    • (2007) J Infect Dis , vol.195 , pp. 1250-1259
    • Blick, G.1    Kagan, R.M.2    Coakley, E.3    Petropoulos, C.4    Maroldo, L.5
  • 9
    • 0033385403 scopus 로고    scopus 로고
    • Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
    • Devereux HL, Youle M, Johnson MA, Loveday C (1999) Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. Aids 13: F123-127.
    • (1999) Aids , vol.13
    • Devereux, H.L.1    Youle, M.2    Johnson, M.A.3    Loveday, C.4
  • 10
    • 0347479194 scopus 로고    scopus 로고
    • Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus
    • Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, et al. (2003) Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 37: 1693-1698.
    • (2003) Clin Infect Dis , vol.37 , pp. 1693-1698
    • Gandhi, R.T.1    Wurcel, A.2    Rosenberg, E.S.3    Johnston, M.N.4    Hellmann, N.5
  • 12
    • 33749036548 scopus 로고    scopus 로고
    • Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: Final results of the CPCRA 064 study
    • Lawrence J, Hullsiek KH, Thackeray LM, Abrams DI, Crane LR, et al. (2006) Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study. J Acquir Immune Defic Syndr 43: 169-178.
    • (2006) J Acquir Immune Defic Syndr , vol.43 , pp. 169-178
    • Lawrence, J.1    Hullsiek, K.H.2    Thackeray, L.M.3    Abrams, D.I.4    Crane, L.R.5
  • 13
    • 0042431969 scopus 로고    scopus 로고
    • Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus
    • Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, et al. (2003) Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 349: 837-846.
    • (2003) N Engl J Med , vol.349 , pp. 837-846
    • Lawrence, J.1    Mayers, D.L.2    Hullsiek, K.H.3    Collins, G.4    Abrams, D.I.5
  • 15
    • 18944399666 scopus 로고    scopus 로고
    • Estimating HIV evolutionary pathways and the genetic barrier to drug resistance
    • Beerenwinkel N, Daumer M, Sing T, Rahnenfuhrer J, Lengauer T, et al. (2005) Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis 191: 1953-1960.
    • (2005) J Infect Dis , vol.191 , pp. 1953-1960
    • Beerenwinkel, N.1    Daumer, M.2    Sing, T.3    Rahnenfuhrer, J.4    Lengauer, T.5
  • 16
    • 18744366364 scopus 로고    scopus 로고
    • Mtreemix: A software package for learning and using mixture models of mutagenetic trees
    • Beerenwinkel N, Rahnenfuhrer J, Kaiser R, Hoffmann D, Selbig J, et al. (2005) Mtreemix: a software package for learning and using mixture models of mutagenetic trees. Bioinformatics 21: 2106-2107.
    • (2005) Bioinformatics , vol.21 , pp. 2106-2107
    • Beerenwinkel, N.1    Rahnenfuhrer, J.2    Kaiser, R.3    Hoffmann, D.4    Selbig, J.5
  • 17
    • 77955402078 scopus 로고    scopus 로고
    • Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing
    • Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, et al. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 5: e11345.
    • PLoS One , vol.5
    • Hedskog, C.1    Mild, M.2    Jernberg, J.3    Sherwood, E.4    Bratt, G.5
  • 18
    • 33745778007 scopus 로고    scopus 로고
    • Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1
    • Hu Z, Giguel F, Hatano H, Reid P, Lu J, et al. (2006) Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol 80: 7020-7027.
    • (2006) J Virol , vol.80 , pp. 7020-7027
    • Hu, Z.1    Giguel, F.2    Hatano, H.3    Reid, P.4    Lu, J.5
  • 19
    • 33646481683 scopus 로고    scopus 로고
    • Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy
    • Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, et al. (2006) Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. Aids 20: 701-710.
    • (2006) Aids , vol.20 , pp. 701-710
    • Palmer, S.1    Boltz, V.2    Maldarelli, F.3    Kearney, M.4    Halvas, E.K.5
  • 20
    • 27144549662 scopus 로고    scopus 로고
    • Interruption of treatment with individual therapeutic drug classes in adults with multidrugresistant HIV-1 infection
    • Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, et al. (2005) Interruption of treatment with individual therapeutic drug classes in adults with multidrugresistant HIV-1 infection. J Infect Dis 192: 1537-1544.
    • (2005) J Infect Dis , vol.192 , pp. 1537-1544
    • Deeks, S.G.1    Hoh, R.2    Neilands, T.B.3    Liegler, T.4    Aweeka, F.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.